Iterum Therapeutics PLC

$0.93
(as of Jul 8, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Iterum Therapeutics PLC

Stock Price
$0.93
Ticker Symbol
ITRM
Exchange
NASDAQ

Industry Information for Iterum Therapeutics PLC

Sector
Healthcare
Industry
Biotechnology

Company Description for Iterum Therapeutics PLC

Country
USA
Full Time Employees
9

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Fundamentals for Iterum Therapeutics PLC

Market Capitalization
$38,556,000
EBITDA
$-15,617,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.94
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
40,000,000
Percent Owned by Insiders
1.03%
Percent Owned by Institutions
6.40%
52-Week High
52-Week Low

Technical Indicators for Iterum Therapeutics PLC

50-Day Moving Average
200-Day Moving Average
RSI
40.72
0.05

Analyst Ratings for Iterum Therapeutics PLC

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About Iterum Therapeutics PLC

Jul 2, 2025, 4:30 PM EST
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum’s newly appointed Chief Commercial Officer. See more.
Jul 2, 2025, 4:30 PM EST
Iterum Therapeutics PLC See more.
Jun 25, 2025, 7:00 AM EST
DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJMEvidence published results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400414. See more.
Jun 11, 2025, 7:00 AM EST